Sign Up Today and Learn More About Proof Diagnostics Stock
Invest in or calculate the value of your shares in Proof Diagnostics or other pre-IPO companies through EquityZen's platform.
Proof Diagnostics Stock (PRDG)
Proof Diagnostics develops CRISPR‑based COVID‑19 molecular tests to help communities take control of their health.
About Proof Diagnostics Stock
Founded
2020
Headquarters
Cambridge, MA, US
Industries
Messaging and Telecommunications, Content and Publishing, Sports
Proof Diagnostics develops CRISPR‑based COVID‑19 molecular tests to help communities take control of their health.
Proof Diagnostics Press Mentions
Stay in the know about the latest news on Proof Diagnostics
Multiplexed nucleic acid detection and modification systems and methods of use
patents • Feb 10, 2025
Methods and compositions for diagnosing diseases
patents • Feb 10, 2025
Coronavirus rapid diagnostics
patents • Feb 10, 2025
Ginkgo Bioworks acquires Proof Diagnostics By Investing.com
investing • Apr 09, 2024
Ginkgo Bioworks Acquires Proof Diagnostics
finsmes • Apr 09, 2024
Proof Diagnostics Management
Leadership team at Proof Diagnostics
Co-Founder
Feng Zhang
Co-Founder
Jonathan Gootenberg
Join now and verify your accreditation status to gain access to:
- Proof Diagnostics Current Valuation
- Proof Diagnostics Stock Price
- Proof Diagnostics Management
- Available deals in Proof Diagnostics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Proof Diagnostics Cap Table and Funding History by Share Class and Liquidity Preferences
- Proof Diagnostics Revenue and Financials
- Proof Diagnostics Highlights
- Proof Diagnostics Business Model
- Proof Diagnostics Risk Factors
- Proof Diagnostics Research Report from SACRA Research
Trading Proof Diagnostics Stock
How to invest in Proof Diagnostics stock?
Accredited investors can buy pre-IPO stock in companies like Proof Diagnostics through EquityZen funds. These investments are made available by existing Proof Diagnostics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Proof Diagnostics stock?
Shareholders can sell their Proof Diagnostics stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
